NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
Financial Comparison: NewAmsterdam Pharma (NASDAQ:NAMS) and Shineco (NASDAQ:SISI)
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 101,409 Shares
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 104,467 Shares
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 94,124 Shares of Stock
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
Johannes Jacob Piete Kastelein Sells 45,481 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 34,400 Shares of Stock
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Franklin Resources Inc. Purchases 78,300 Shares of NewAmsterdam Pharma Company N.V. $NAMS
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating
Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3.65% Impact
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates